Roche Q1 sales plain as Illumina bid conflict rages

<p>ZURICH (Reuters) Swiss drugmaker Roche pronounced it would have to rethink a strategy if shareholders of demure U.S. bid aim Illumina did not behind a proceed as it reported clever first-quarter curative sales helped by tip cancer drugs.
Genetics dilettante Illumina has deserted Roches $6.8 billion honeyed takeover offer and urged investors to opinion opposite Roches bid to get a possess nominees on to a U.S. firms house during a assembly on Apr 18 to pull for talks.
Chief Executive Severin Schwan told reporters on Thursday that Roche would have to cruise all a options if Illumina shareholders voted opposite a proposals during that meeting.
Roches efforts to get a line-up of directors inaugurated to Illuminas house demeanour to be a prolonged shot after 3 substitute advisory firms have endorsed that shareholders behind Illuminas nominees.
If Illumina were to rivet with us, we would cruise any information ancillary Illumi...